SmartCella is a global innovative biotechnology company that combines novel delivery platforms, such as the Extroducer, with cutting-edge cell and mRNA therapies. The Extroducer is a first-in-class endovascular delivery device that enables direct-to-tissue drug delivery. It addresses a significant unmet clinical need for a wide range of indications, enabling targeted delivery of various modalities to solid tumors and hard-to-reach tissues, including the heart. The Extroducer provides access to these areas by safely penetrating the vessel wall and delivering payload directly to the target location. It can be used in combination with standard imaging equipment and routine interventional radiology approaches.
The patent granted by the EPO is the next generation of patents related to the Extroducer delivery platform. This specific patent covers the design of the distal part of the Extroducer, which penetrates the vessel wall and moves smoothly towards the target location. The patent provides protection in 39 relevant countries and is going to remain valid for 20 years, per global patent standards.
Niklas Prager, CEO, comments: “We are pleased to have been granted an additional patent for the Extroducer, further strengthening our intellectual property portfolio and solidifying our market position. As the Extroducer is a unique and highly innovative delivery platform, it requires a strong, enduring patent foundation. This is a key element of our go-to-market strategy, enabling our partners to gain a competitive advantage with a minimally invasive route of administration for their therapeutic portfolios. It is essential to protect the Extroducer platform and ensure that the work within our partnerships cannot be duplicated throughout the process, from clinical trials to full commercialization.”
